Evidence map›Paper›PMID 39727397›Full record

ArticleJournal of bacteriology2025

MtlD as a therapeutic target for intestinal and systemic bacterial infections.

Andrew Schwieters, Allysa L Cole, Emily Rego, Chengyu Gao, Razieh Kebriaei, Vicki H Wysocki, John S Gunn, Brian M M Ahmer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bacteriology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Infection and immunity · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrew SchwietersDepartment of Microbiology, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0003-3594-8128
Allysa L ColeInfectious Diseases Institute, The Ohio State University, Columbus, Ohio, USA.
Emily RegoDepartment of Microbiology, The Ohio State University, Columbus, Ohio, USA.
Chengyu GaoCampus Chemical Instrument Center, The Ohio State University, Columbus, Ohio, USA.
Razieh KebriaeiDepartment of Outcomes and Translational Sciences, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0003-4019-2679
Vicki H WysockiInfectious Diseases Institute, The Ohio State University, Columbus, Ohio, USA.
John S GunnInfectious Diseases Institute, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0003-2848-8346
Brian M M AhmerDepartment of Microbiology, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-4267-7322

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Microbial ecology of the inflamed intestineR01AI143288 · NIAID · OHIO STATE UNIVERSITY · PI AHMER, BRIAN M, WRIGHTON, KELLY C · 2018 to 2022
$3.5M
Salmonella-specific therapeuticsR01AI140541 · NIAID · OHIO STATE UNIVERSITY · PI AHMER, BRIAN M, GOPALAN, VENKAT · 2018 to 2021
$2.8M
GENETIC ANALYSIS OF RNA VIRUS-HOST INTERACTIONR01AI043288 · NIAID · WASHINGTON STATE UNIVERSITY · PI CARRINGTON, JAMES C · 1998 to 2007
$1.7M
Interdisciplinary Program in Microbe-Host BiologyT32AI165391 · NIAID · OHIO STATE UNIVERSITY · PI RAJENDAR K DEORA, Daniel J Wozniak · 2022 to 2026
$1.5M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1R01AI140541HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1R01AI143288NCI NIH HHS P30 CA016058NIAID NIH HHS R01 AI043288NIAID NIH HHS R01 AI140541NIAID NIH HHS R01 AI143288NIAID NIH HHS T32 AI165391
6 · The paper itself

Abstract

The ability to treat infections is threatened by the rapid emergence of antibiotic resistance among pathogenic microbes. Therefore, new antimicrobials are needed. Here we evaluate mannitol-1-phosphate 5-dehydrogenase (MtlD) as a potential new drug target. In many bacteria, mannitol is transported into the cell and phosphorylated by MtlA, the EIICBA component of a phosphoenolpyruvate-dependent sugar phosphotransferase system. MtlD catalyzes the conversion of mannitol-1-phosphate (Mtl-1P) to fructose-6-phosphate, which enters the glycolytic pathway. Mutants lacking IMPORTANCE: The ability to treat infections is threatened by the rapid emergence of antibiotic resistance. Mannitol is a polyol used in human medicine and the food industry. During catabolism of mannitol, many bacteria transport mannitol across the inner membrane forming the toxic intermediate mannitol-1-phosphate (Mtl-1P). Mtl-1P must be processed by mannitol dehydrogenase (MtlD) or it accumulates intracellularly, causing growth attenuation. We test and confirm here that

Indexed as

Anti-Bacterial AgentsBacterial ProteinsMannitol DehydrogenasesAnimalsEscherichia coliFemaleMannitolMicePseudomonas aeruginosaSalmonella entericaSugar Alcohol DehydrogenasesAnti-Bacterial AgentsBacterial ProteinsMannitolmannitol-1-phosphate dehydrogenaseMannitol DehydrogenasesSugar Alcohol DehydrogenasesCronobacter sakazakiiEscherichia colimannitolMtlDPseudomonas aeruginosaSalmonellasugar-phosphate toxicity

Identifiers

PMID39727397
PMCPMC11784389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.